Biomedicine Daily · Tuesday, 13 October 2026
CBA FRONTIER INSIGHTS
BMS RayzeBio Bet Pays Off With First Phase 3 Alpha Radiopharmaceutical Win
Bristol Myers Squibb's RYZ101, an actinium-225-based radiopharmaceutical acquired in the $4.1 billion RayzeBio deal, met its primary endpoint in an interim analysis of the Phase 3 ACTION-1 study, showing a statistically significant and clinically meaningful improvement in progression-free survival by blinded independent central review. The trial enrolled patients with advanced somatostatin receptor-expressing GEP-NETs that progressed after Lutathera. These are the first Phase 3 results for an alpha-isotope targeted radiopharmaceutical therapy in any indication, a proof point for a field that has drawn billions in dealmaking. The day also brought a 60.4% proptosis response rate for IBI311 in Phase 3 inactive thyroid eye disease, a Phase 3 win for BMS's admilparant in IPF despite a high-dose miss, and the first Phase III success for an individualized neoantigen mRNA cancer vaccine.
Clinical readouts and safety
IBI311 Hits 60.4% Proptosis Response in Phase 3 Inactive Thyroid Eye Disease Trial
IBI311 met its primary endpoint in the Phase 3 RESTORE-3 trial in inactive thyroid eye disease, with a proptosis response rate of 60.4%. The multicenter, randomized, double-blind, placebo-controlled study enrolled 116 patients randomized about 2:1 to IBI311 or placebo. Prior clinical evidence for IBI311 came mainly from patients with active TED.
RevMed's Rasonque gets a subtype data asterisk, but analysts remain bullish
FDA review documents show that Revolution Medicines' RAS inhibitor Rasonque, approved early for pancreatic adenocarcinoma, performed unevenly across KRAS mutation subtypes in the Phase 3 RASolute 302 trial. Overall ORR was 33%, but patients with G12V mutations reached 50%, G12D patients 24%, and the small G12R cohort just 7%, below the chemotherapy control. Analysts at Leerink and Truist called the gap exploratory and still expect a record launch, with Truist projecting $2.3 billion in sales by 2028 if the drug moves into first-line disease.
BMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma win
Bristol Myers Squibb's RYZ101, an actinium-225-based radiopharmaceutical acquired in the $4.1 billion RayzeBio deal, met the primary endpoint in an interim analysis of the Phase 3 ACTION-1 study, showing a statistically significant and clinically meaningful improvement in progression-free survival by blinded independent central review. The trial enrolled patients with advanced somatostatin receptor-expressing GEP-NETs that progressed after Lutathera, and these are the first Phase 3 results for an alpha-isotope targeted radiopharmaceutical therapy in any indication.
BMS’ Phase 3 win for lung drug clouded by high-dose miss
Bristol Myers Squibb's LPA1 antagonist admilparant met the primary endpoint in the Phase 3 ALOFT-IPF study, with the 60-mg dose showing a statistically significant improvement over placebo in absolute change in FVC from baseline at week 52, while the 120-mg dose missed significance on the same measure. The drug was well tolerated across both doses, with discontinuations due to adverse events comparable to placebo. Analysts said the results could support approval and validate the LPA1 mechanism, but the lack of dose response raises questions; BMS plans to meet health authorities ahead of regulatory submissions.
First Phase III Success for Individualized Neoantigen mRNA Cancer Vaccine
An mRNA cancer therapeutic vaccine has delivered a positive Phase III readout, the first individualized neoantigen therapy and the first mRNA tumor treatment product to succeed at Phase III. The trial enrolled 1137 patients randomized 2:1. The result establishes that this development route can work, not that vaccines cure cancer.
AstraZeneca ALXN1850 Fails Hypophosphatasia Trial Primary Endpoint
AstraZeneca's ALXN1850 (efzimfotase alfa) missed the primary endpoint in a trial in hypophosphatasia. The 6MWT increased by 17.05 meters in the efzimfotase alfa group, with a p-value of 0.1675, so the difference was not statistically significant. Subgroup analysis indicated a more pronounced treatment effect in patients with childhood-onset disease.
First Tracks climbs on ‘impressive’ celiac study data
ANB033, a CD122-blocking antibody from First Tracks Biotherapeutics, produced a statistically significant improvement over placebo in protecting the intestinal lining from gluten-induced damage in an early-stage celiac disease trial. The 32 participants received three subcutaneous doses or placebo over four weeks, then a two-week gluten challenge equivalent to about two slices of bread daily; the drug hit significance on three biological measures with no related serious adverse events. A second cohort reports in early 2027, with a late-stage trial planned that year.
doi.orgComparative efficacy of topical garlic extract and 20% podophyllin solution in the treatment of female genital warts: a triple-blind randomized clinical trial
Topical 5% garlic extract worked as well as 20% podophyllin solution for female genital warts in a triple-blind randomized trial of women treated weekly for four weeks. Mean wart size fell from 1.61 to 0.60 mm with garlic and from 2.96 to 0.62 mm with podophyllin, with no significant between-group difference (p = 0.756). Complete response occurred in 51.4% of each group, offering a low-cost alternative where no single therapy gives consistent clearance.
clinicaltrials.govIdiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets
Trevi Therapeutics has registered a Phase 3 trial (NCT07868419) testing nalbuphine extended-release (NAL ER) tablets against placebo for chronic cough in participants with idiopathic pulmonary fibrosis. The trial plans to enroll 201 people, with a planned start of 2026-09-30 and first registration on 2026-10-09; its primary purpose is to evaluate the safety and efficacy of NAL ER in this population.
clinicaltrials.govStudy of ORJ-001 for the Treatment of IPF
A newly registered Phase 2 trial (NCT07869147), sponsored by Oorja Bio, Inc., will enroll 95 patients with idiopathic pulmonary fibrosis to test ORJ-001 against placebo. Part A will assess tolerability and how long the drug stays in the body; Part B will test its effect on lung function. Animal models of IPF showed ORJ-001 can repair damaged lung tissue and improve markers of lung function. Recruitment is planned to start in October 2026.
Regulatory and policy
RevMed’s pancreatic cancer drug first
The FDA approved Revolution Medicines' Rasonque (daraxonrasib) in August for metastatic pancreatic adenocarcinoma, making it a first-in-class RAS inhibitor for the most common form of pancreatic cancer. Rasonque uses a molecular glue mechanism, binding cyclophilin A and RAS in its GTP-bound 'on' state, unlike KRAS G12C inhibitors such as Lumakras and Krazati. An early-stage trial in September showed promise in lung cancer, raising hopes for use in other hard-to-treat tumors.
FDA nod for rare neurology drug
The FDA has approved Ionis Pharmaceuticals' Zanvastro (zilganersen), the first disease-modifying drug for Alexander disease, a rare progressive and often fatal neurological condition affecting about one person per 1-3 million. The antisense oligonucleotide targets RNA encoding glial fibrillary acidic protein (GFAP), reducing its overproduction in astrocytes, where excess GFAP forms clumps that disrupt myelination. Patients suffer impaired motor function, seizures, intellectual disability and developmental delays.
Hiding in Plain Sight: 7-OH Products
DEA issued two new Notices of Intent on October 9, 2026, based on updated HHS analysis, proposing threshold-based Schedule I control for 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MGPI). HHS recommends Schedule I when either substance, or their combined amount, exceeds 1 milligram per gram in solids or 1 milligram per milliliter in liquids, or when the mitragynine ratio to them falls below 100 to 1. DEA will reissue its Notice of Intent without changing the current scheduling approach for MGM-15 and MGM-16, which were temporarily placed in Schedule I on August 26, 2026; controls stay in effect during the 30-day notice period and until a new temporary scheduling order.
Roche files for approval of IL-6 antibody vamikibart in uveitic macular edema after Phase III data
Roche has submitted vamikibart, an IL-6 antibody for uveitic macular edema, for marketing approval after presenting 52-week data from the two Phase III trials MEERKAT and SANDCAT at AAO 2026. The results showed sustained vision improvement and reduced macular thickness. If approved, vamikibart would be the first non-steroidal targeted therapy for Uveitic macular edema, where high-dose steroids are currently the main option.
Industry and deals
Parkinson’s cell therapy developer files to go public
Aspen Neuroscience, founded in 2018, has filed registration documents to list on the Nasdaq under ticker "ASPE" and would be the first Parkinson's-focused cell therapy developer to go public in the U.S. Its lead therapy sasineprocel, or ANPD001, reprograms a patient's own cells into dopamine-producing neurons and is entering late-stage testing after an early-stage trial. Aspen has raised about $347 million, posted a $62 million net loss in 2025 and nearly $37 million in the first six months of this year, and warned of substantial doubt about its ability to continue as a going concern without substantial additional capital.
Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data
Bausch + Lomb named board chair Thomas Appio interim CEO after he and Brent Saunders mutually agreed to Saunders' exit, and raised its 2026 earnings outlook. Merck disclosed that proliferative diabetic retinopathy adverse events occurred in 6.7% and 6.1% of remigromig patients versus 0.9% on Lucentis, with the drug not superior on secondary measures. Amgen and AstraZeneca reported nearly 70% of eosinophilic esophagitis patients on Tezspire's highest dose were in remission at 24 weeks; the FDA also approved Asahi Kasei's Hovilpri.
Research papers
Antiviral immunity via telomerase-like reverse transcription in bacteria
A new bacterial antiviral defense system, DRT10, uses a reverse transcriptase paired with a noncoding RNA to synthesize tandem-repeat DNA in a protein-primed, boundary-delimited manner that mirrors telomeric repeat addition by eukaryotic telomerase. Cryo-EM shows an unanticipated 2:1 complex in which two RT monomers bind opposite sides of a pseudo-symmetric ncRNA, but only one produces the long repetitive product. Phylogenetic analyses place telomerase in a monophyletic clade with the DRT family, suggesting a common evolutionary origin for their DNA polymerization activities.
Micronuclear ecDNA constrains tumor cell fitness and is associated with favorable patient survival
Single-micronucleus sequencing and live-cell imaging of cancer cells, together with analyses of neuroblastoma biopsies, show that extrachromosomal DNA (ecDNA) residing in micronuclei constrains tumor cell fitness. In patients with neuroblastoma, micronuclear ecDNA was associated with favorable survival. The work identifies micronuclear localization of ecDNA as a feature linked to reduced tumor fitness rather than unchecked growth.
Nature Study Confirms Adult Hippocampus Keeps Making New Neurons and Maps Cognitive Aging
A multi-omics study of human hippocampal tissue published in Nature confirms that the adult human brain continues to generate new neurons. Using single-cell transcriptomics and chromatin accessibility sequencing on hippocampal samples from people with different cognitive states, the work resolves a long-standing debate over neurogenesis in the dentate gyrus and links it to memory, resilience against cognitive decline, normal aging and Alzheimer's disease.
SMCHD1 is a target for gene activation therapy to treat Prader-Willi syndrome.
SMCHD1 represses the entire Prader-Willi syndrome locus in neural lineages in both mice and humans, making it a candidate target for activating the silenced maternal copy of the disease genes. Deleting Smchd1 after early development in vivo activated PWS genes in disease-relevant mouse tissues including hypothalamus and improved phenotypes in a PWS mouse model. Genome-wide SMCHD1 binding aside, this postearly targeting appeared safe, supporting gene activation therapy for the underlying cause of PWS rather than individual symptoms.
A health-system-scale, episode-resolved multimodal atlas of cancer cachexia
A multimodal atlas of cancer cachexia built from longitudinal data on 52,236 patients with cancer shows that weight loss episodes are linked to systemic serologic signatures and specific tumor genotypes. Integrated clinical and molecular data predicted these episodes, enabling earlier identification of cachexia.
Real-time single-molecule imaging in zebrafish embryos uncovers noncanonical translation.
Real-time single-molecule imaging of bmp2b translation in early zebrafish embryos, using ALFA array-based nascent chain labeling and lattice light-sheet microscopy, shows that only some bmp2b mRNAs are actively translated, so limited mRNA translation competence constrains efficiency. Replacing bmp2b UTRs with viral UTRs increased ribosome loading, and the bmp2b 5'UTR, unlike actb2, supported cap-independent translation with ribosome loading comparable to cap-dependent initiation. The work delivers a quantitative in vivo framework for translation kinetics in vertebrate development.
Population-scale reconstruction of menopause dynamics reveals a physiological cliff at the final menstrual period
The final menstrual period marks an abrupt, multisystem physiological shift rather than a gradual decline, according to a cross-sectional analysis of laboratory data from two independent cohorts using a new computational framework. Sex hormone changes begin more than 10 years before menopause onset, meaning menopause dynamics can be reconstructed at population scale and dated physiologically, not just clinically.
Tracing the origins of CRISPR–Cas
VIPR systems, a family of RNA-guided DNA-targeting systems found mainly in bacteriophages, may be evolutionary precursors to class 1 CRISPR-Cas. Yoon and colleagues identified them through structure-based searches of the AlphaFold database and showed that small Vipr proteins bind VIPR RNAs with tandem repeats. The NN bases guide DNA targeting through a 'one-nucleotide skip' code, validated in vitro and by transcriptional repression in Escherichia coli, and reprogramming the NN sequences redirects targeting without a protospacer-adjacent motif.
A CK2-β-TrCP kinase-E3 ubiquitin ligase cascade is a metabolic sensor regulating tryptophan 2,3-dioxygenase stability
A CK2 kinase–β-TrCP E3 ubiquitin ligase cascade controls the stability of the tryptophan-metabolizing enzyme TDO2 in response to substrate availability. When tryptophan occupies an exosite on TDO2, the degron is shielded; at low tryptophan, the degron becomes accessible, driving phosphorylation- and ubiquitylation-mediated degradation of the enzyme.
PHYHD1-mediated translational control regulates renal cell carcinoma progression
PHYHD1 acts as a tumor suppressor in renal cell carcinoma by controlling protein production. Its loss drives disease progression through increased production of ceramide transporter 1 (CERT1). The PHYHD1-CERT1 regulatory pathway may help predict patient outcomes and offers a therapeutic opportunity for PHYHD1-deficient tumors.
Trastuzumab deruxtecan kills skin and uveal melanoma in vivo by HER2-independent payload release
Trastuzumab deruxtecan (T-DXd) inhibited all subcutaneous melanoma PDXs and outperformed trastuzumab emtansine (T-DM1), which had limited activity, while liver models were less sensitive. Parental and ERBB2-knockout xenografts responded similarly at first, though knockout tumors regrew earlier, and melanoma cells resisted both ADCs in vitro with little trastuzumab uptake. Tumor-derived cathepsin L found outside melanoma cells suggests payload release can occur extracellularly, independent of HER2.
doi.orgVagal sensing of altered gut microbiota links to externalizing behaviors
Sirtuin 3 (Sirt3) deficiency in mice produces externalizing, mood-related behaviors together with altered gut microbiome composition, elevated plasma choline, reduced GABA in the nucleus of the solitary tract, and changed expression of synaptic plasticity-related genes in the amygdala and BNST. Subdiaphragmatic vagotomy reversed these measures, making vagotomized Sirt3-knockout mice similar to wild-type mice. The work places the vagus nerve as the conduit linking host genetics, gut microbiota, and behavior.
Malignant and stromal partial EMT programmes and cetuximab outcome in head and neck cancer
Standard bulk partial EMT (pEMT) scores in head and neck squamous cell carcinoma mainly measure stroma: across three single-cell datasets, the malignant arm (laminin-332 and hemidesmosome genes) sat in malignant cells while the stromal arm (fibrillar collagens, vimentin) sat in fibroblasts. A classifier and 12-gene core recovering the malignant arm predicted long progression-free survival in 40 patients given platinum and cetuximab (AUC 0.78 and 0.82), but the malignant arm tracked the Basal subtype, whose score performed as well or better (0.93) and also in two xenograft panels.
Radiotherapy Reshapes the 3D Genome in Medulloblastoma Cells
A single 2 Gy dose reorganized the 3D genome and rewired transcription and protein expression in ONS-76 medulloblastoma cells, shifting chromatin towards active A compartments, forming new TAD boundaries, and transiently strengthening existing ones while global genome organisation stayed stable. Integrated RNA-seq, proteomics, and Micro-C pointed to LAMB3 and AKR1B10 as candidate mediators of radioresponse that stayed elevated after fractionated irradiation. This is the first genome-wide picture of radiation-induced chromatin reorganisation in a medulloblastoma model.
The effects of improved access to diabetes medications on risk of Alzheimer's disease and related dementias.
A dynamic microsimulation using 10 years of data on Americans aged 51 and older with diabetes estimates that increased utilization of GLP1s and SGLT2s by people with diabetes and HbA1c > 7 could avert 76,000-201,000 cases of Alzheimer's disease and related dementias over 10 years. Risk reduction is largest for Black and Hispanic individuals and those with HbA1c > 8, pointing to access and adherence for high-risk groups as the target with the largest benefit.
Methods and resources
Award-winning microscopy image disqualified over AI use
Nikon Instruments disqualified the first-place entry in its Small World in Motion microscopy competition on 9 October after scientists flagged features in the video of beating airway cilia as biologically implausible. The entrant, optical engineer Ning Xu, said an AI model was used in post-processing to enhance regions below the cilia; competition rules prohibit AI-generated videos. Nikon said the decision concerns eligibility only, not the entrant's reputation or intent.
A reference-calibrated spatial-statistical framework for quantifying stroma-tumor cell spatial associations from histology and its geometric limits
A framework combining four spatial statistics with specimen-specific reference states recovers the presence, range, and strength of spatial associations directly from segmented histology, without requiring interaction models specified a priori. In controlled in silico tissues, tissue stromal architecture imposed geometric limits on recoverable interaction ranges, with event fraction constraining statistical sensitivity. Applied to an ALK+ NSCLC model during tyrosine kinase inhibitor therapy, it identified a strong stroma-associated proliferation bias of proliferating tumor cells relative to CAF-rich stroma extending approximately 30-60 micrometers.
Live-cell imaging goes WHOLISTIC
WHOLISTIC is a live-imaging platform that records cellular activity across the entire vertebrate body at single-cell resolution, using genetically encoded calcium sensors, high-speed volumetric fluorescence imaging, computational motion correction and tissue-scale activity analysis. Ruetten and colleagues built transgenic zebrafish expressing a calcium indicator in nearly all cell types and demonstrated the approach in adult Danionella cerebrum, with whole-body expansion microscopy supporting molecular and anatomical characterization of cell populations.
Private, offline and yours: how to search the literature with local AI systems
Growing numbers of researchers are running large language models offline on their own machines, using tools such as Ollama and LM Studio to sort, query and index their literature libraries while keeping sensitive data out of cloud systems. A 2025 analysis found that six major AI developers trained models on users' input data by default, and a Wiley survey of some 2,400 researchers found 68% had used AI for literature searches or reviews. Local setups trade some capability, such as internet-based literature search, for privacy, reproducibility and free inference.
Alignment-Aware Genomic Coordinate Encoding for Long-Range DNA Modeling
USM-AA is a genomic foundation model that encodes reference genome coordinates through a non-contiguous positional encoding called Alignment-Aware Rotary Position Embedding, plus an alignment embedding capturing chromosome, strand, and CIGAR information. It uses reverse-complement masked learning to improve long-range sequence modeling and was pretrained on alignment-aware sequences spanning cross-species evolution and human population variation. USM-AA consistently outperforms existing models across multiple downstream tasks, supporting alignment-aware representations for modeling distal regulatory elements and sparse motifs.
Opinion and commentary
[News] Impact of the Trump Administration on the Affordable Care Act
On Sept 22, 2026, the US Government cancelled government-subsidised health insurance policies for more than 760,000 people, contending the policies were fraudulently obtained on the Federal Health Insurance Marketplace. Officials said up to 440,000 further enrolments remain under investigation, leaving those coverage decisions pending.
Pharma’s $500B patent problem will come in waves — not as a cliff
Evaluate forecasting data from Norstella show more than $500 billion in worldwide prescription drug sales at risk from generic competition between 2026 and 2032, with the largest single-year exposure of $158 billion in 2031. Merck is most exposed near term as Keytruda nears expiry in 2028, a year with $99 billion in sales at risk, while AbbVie faces roughly $50 billion of exposure in 2032 when Rinvoq and Skyrizi lose protection. Patent-exposed companies have responded with dealmaking since the start of 2024, led by Merck's six deals totalling $30.9 billion and Lilly's $27.2 billion across nine.
In brief
Also today
2 events that did not make today's daily, one table per category, one row per event. Open a category to expand.
OtherGSK · PhRMA2 ▾▴
Everything else with a concrete event that did not make the daily.
- GSKUpdateGSK will invest more than $800 million to build an innovation and manufacturing hub in Upper Merion Township, Pennsylvania, adding a biologics production facility, an R&D pilot plant, a centralized quality control lab and a manufacturing science and technology hub. Demolition and construction start next year. Pennsylvania officials expect more than 300 new jobs over five years, with about 4,500 existing jobs retained, and the project is eligible for state tax benefits.
- PhRMAUpdatePhRMA sued CMS in the US District Court for the District of Columbia on October 7 over Medicare's Global Benchmark for Efficient Drug Pricing (GLOBE) model, arguing the rule is unlawful and exceeds the agency's statutory authority. PhRMA is asking the court to vacate the entire rule, which the Trump administration finalized on September 30 as part of its drug pricing efforts.